Top alley oops from Minnesota Timberwolves vs. Charlotte Hornets, 03/03/2021
SpaceX is launching another crewed mission for NASA on Friday. Here's what to know about the launch.
(Bloomberg) -- Turkey launched an international manhunt for the founder of one of its major cryptocurrency exchanges after he stopped paying clients and fled the country.The Justice Ministry is seeking a so-called red notice under which Interpol would help find, provisionally arrest and return Thodex Chief Executive Officer Faruk Fatih Ozer from Albania to Turkey, state-run Anadolu Agency reported Friday.Turkish police have detained 62 people in eight cities including Istanbul, where Thodex was based, while 16 others remain at large, it said.Turkish Crypto Exchange Goes Bust as Founder Flees CountryIn a statement from an unknown location on Thursday, Ozer promised to repay investors and to return to Turkey to face justice at a later date. The government moved to block the company’s accounts and police raided its head office in Istanbul.Losses could be as high as $2 billion, according to Haberturk newspaper, and a lawyer for the victims said the money invested by about 390,000 active users had become “irretrievable.”Both figures have been disputed by Ozer. About 30,000 users have been affected, he said in a statement on the company’s website Thursday.Thodex was part of the cryptocurrency boom that has drawn in legions of Turks seeking to protect their savings from rampant inflation and an unstable currency. Inflation hit 16.2% in March, more than three times the central bank’s target of 5%. The Turkish lira has weakened 10% against the dollar this year, its ninth consecutive year of losses.(Releads with international manhunt)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
"It was one of the grossest moments of my life."
Pubs, cafes and restaurants will reopen in Wales and Scotland on Monday 26 April.
Futures rose, Bitcoin dived below $50,000, after the Biden capital gains tax plan hit stocks. Intel, Snap are key movers.
Richard Glenn, 55, has been banned from teaching after being found guilty of unacceptable professional conduct after getting drunk with pupils on a trip to Costa Rica and threatening them.
ChenMed, a national leader in primary care for underserved seniors, today announced that Atlanta resident James B. "Buck" McCabe has joined its Board of Directors to help the company keep strengthening its culture in a period of sustained hyper growth.
Major players in the chimeric antigen receptor -T therapy market are Novartis AG, Kite Pharma, Pfizer Inc, Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics, and Legend Biotech.New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "CAR-T Therapy Pipeline Analysis Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06065184/?utm_source=GNW The global car-t therapy pipeline analysis market is expected to grow from $1.08 billion in 2020 to $1.4 billion in 2021 at a compound annual growth rate (CAGR) of 29.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $3.15 billion in 2025 at a CAGR of 22%.The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers.CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient.This special protein receptor, known as chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs.North America was the largest region in the global car-t therapy pipeline analysis market, accounting for 61% of the market in 2019. Western Europe was the second largest region accounting for 38% of the global regional preview market.The CAR-T therapy market covered in this report is segmented by target antigen into CD19, CD22, others. It is also segmented by application into acute lymphoblastic leukaemia, diffuse large b-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, multiple myeloma, others.The limitations on the application of CAR-T therapy limits the growth of the market.The limitations on CAR-T therapy includes its failure to treat other types of cancer, side effects and the high cost of treatment.CAR-T therapy is widely used as a treatment for a particular type of blood cancer and fails to treat other types of cancers such as lung cancer or breast cancer.Further, in many cases the application of CAR-T therapy results in cytokine release syndrome (CRS).CRS is severe flu like condition causing high fever, nausea, chills, headache, rash, and troubled breathing.Further, the high cost limits the growth of the market.According to an article in HealthLeaders in 2019, the cost of one CAR-T therapy session can be up to $375,000 excluding the overhead charges such as hospital bills. Thus, the growth of the CAR-T therapy is restricted by the various limitations on the application of CAR-T therapy.The companies in the CAR-T therapy market are conducting clinical trials to assess the ability of CAR-T therapy to treat multiple myeloma.Multiple myeloma is a type of white blood cell cancer where the cancer cells accumulate in the bone marrow and surrounds the healthy blood cells.CAR-T therapy is being tested as a treatment for multiple myeloma.CAR-T cells are modified to target the multiple myeloma causing cells to treat the relapsed or refractory multiple myeloma (RRMM).For instance, Sorrento Therapeutics, a USA based developer of therapeutic approaches to treat different types of cancer, developed CAR2 anti-CD38 CAR-T cell therapy to treat RRMM. The CAR2 anti-CD38 CAR-T cell therapy is in phase 1 of its clinical trial with 72 participant recruitments made by the end of 2019.The aim of the clinical trial is to evaluate the efficiency and safety of CAR2 anti-CD38 CAR-T cell therapy. The trial is expected to be completed in 2020.In 2019, Novartis, a Switzerland based global medicines company, acquired CellforCure for an undisclosed amount.The acquisition is aimed to increase Novartis’ internal production capacity for cell and gene therapies.CellforCure is a French based contract development and manufacturing organization (CDMO) that provides manufacturing facility for cell and gene therapy. CellforCure assisted Novartis in 2017 to manufacture CAR-T treatment named Kymriah.The CAR-T therapy market is driven by the increasing financial support provided by different organizations to promote the development and consumption of CAR-T therapy.The government and non-government organizations provide financial support to the companies in CAR-T therapy market for research and development and to the patients for their treatment of acute lymphoblastic leukaemia (ALL).For instance, in 2019, the Ministry of Business, Innovation and Employment of New Zealand announced its contribution of $4.9 million over 5 years to its partnership scheme with Malaghan Institute (MI), in order to support the development of CAR T-cell manufacturing in New Zealand. Further, governments in some countries provide subsidy to patients undergoing CAR-T therapy owing to the high cost of the treatment. For example, in 2019, the government of Australia included the CAR-T therapy on the Medicare Benefits Schedule (MBS). The inclusion of (Kymriah®) CAR-T therapy in MBS reduces the cost of the treatment for almost 30 paediatric and young adult (ALL) patients per year in Australia. The financial support provided by different organizations towards CAR-T therapy positively drives the growth of CAR-T therapy market.Read the full report: https://www.reportlinker.com/p06065184/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
The "CBD Nutraceuticals Market Share, Size, Trends, Industry Analysis Report, By Product; By Distribution Channel; By Region; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
France's President Macron is among foreign leaders to pay their last respects to Idriss Déby.
Personally, I like my movie experience to involve a cohesive storyline. But that isn't possible with a movie like Late Shift.
SAN DIEGO, April 23, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company"), a company focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, is very excited to announce it has entered into a letter of intent (the "LOI") to acquire Bohemian Beverage Co. Bohemian Beverage Co. is a profitable, revenue-generating entity with an extraordinary brand portfolio of more than 20 unique beverage brands, including CBD-infused teas, ginger ale, beers, ciders, cocktails and more, which are directly distributed and sold through the company’s own subsidiary storefront. The company was also the very first brewery, cidery, distillery and manufacturer of CBD beverages in the state of Virginia. By creating stylish, youthful, sexy branding, promoted by skillful marketing through social media and successful event planning, they have sustained interaction, engagement and participation from their target market. The current demand for Bohemian Beverage Co. products is outpacing the current production capabilities. To meet the growth, the next step in their expansion is to build a state-of-the-art production facility that has the capability and licencing to produce beer, distilled spirits, cider, wine, CBD-infused and nonalcoholic beverages. This serves to leverage both existing and new distribution networks to grow current brands and expand upon brands in development. As part of this transaction, Green Hygienics will invest in the construction of a larger bottling facility, “The Grove Brewery,” that is combined with a farmers’ market on a 5-acre land parcel ideally situated on Portsmouth Boulevard in Chesapeake, Virginia. Virginia became the first Southern state to legalize marijuana just two weeks ago, as lawmakers voted to approve Gov. Ralph Northam's proposed changes to a bill that will allow adult cannabis use starting in July 2021. “The beverage sector is very competitive and there is a steep learning curve. This strategic acquisition will allow us to enter the CBD-infused drink market supported by expertise and existing distribution while mitigating risk, and more significantly will bring immediate revenue and hard assets to our financials. When you compare this brand portfolio to any of the large marketers in the space, it quickly becomes evident what extraordinary potential exists in this opportunity,” stated Ron Loudoun, CEO of Green Hygienics. “Consider the margins in this business model where you create, manufacture, retail (at your own facility) and distribute, as well! We are very excited about entering this lucrative market and launching our beverage division in such a sensible manner. Green Hygienics can provide a strategic advantage in the marketplace by introducing novel cannabinoids and targeted bio-delivery technologies to the formulations. The Bohemian Beverage Co. team has laid the foundation for something fantastic. We look forward to working with them and taking this to the next level.” About Bohemian Beverage Co. We brew and we brand, and we’re socially unconventional. Bohemian Beverage Co. is a beer and libations think tank and hatchery. We produce our own industry-disrupting potables while lending our brewing and branding services to like-minded creators. We’re fueled by the beverage market’s constant innovation. Our team of industry experts is always scanning for unchartered waters, allowing us to sit at the forefront of trends and developments. We’re a passionate crew who deliver high-quality products to human beings everywhere. https://backbaybrewingco.com https://farmhousebrewingva.com About Green Hygienics Holdings Inc. Green Hygienic Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”) is a California-based innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids. www.greenhygienics.com Facebook, Twitter and LinkedIn CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTSThis document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. Corporate Communications:InvestorBrandNetwork (IBN)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
Dublin, April 23, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes and evaluates the molecular diagnostics technologies that will play an important role in the practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions, is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in the development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been considerable interest in developing rapid diagnostic methods for point-of-care and biowarfare agents such as anthrax. Molecular diagnostic tests for COVID-19 are described.The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 268 of these are profiled in the report along with tabulation of 657 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2020 according to technologies, applications and geographical regions. Forecasts are made up to 2030. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.Benefits of this report This report has evolved during the past 25 years, profiting from feedback by numerous readers and experts.The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.Includes profiles of 268 companies, the largest number in any report on this topic.500 references, cited in the report are included in the bibliography.The text is supplemented by 103 tables and 17 figures. Who should read this report? Chief executive officers of molecular diagnostic companies.Business development executives of pharmaceutical and biotechnology companies.Executives of companies involved in developing integration of diagnosis and treatment as well as those interested in personalized medicine.Officers of genomic and proteomic companies interested in diagnostic technologies.Research scientists involved in the application of molecular diagnostic technologies.Planners of healthcare services. Key Topics Covered: Part One Executive Summary 1. Introduction Definitions and scope of the subjectHistorical evolution of molecular diagnosticsMolecular biology relevant to molecular diagnosticsDNADNA polymerasesRestriction endonucleasesRNARNA polymerasesNon-coding RNAsDNA transcriptionChromosomesChromatinExtrachromosomal DNATelomeresMitochondrial DNAGenesThe genetic codeGene expressionThe human genomeENCODEVariations in the human genomeVariations in DNA sequencesSingle nucleotide polymorphismsHaplotypingCopy number variations in the human genomeGenotype and haplotypesGenomic imprintingInsertions and deletions in the human genomeComplex chromosomal rearrangementsLarge scale variation in human genomeStructural variations in the human genomeReplication of the DNA helixTransposonsEpigenetics/epigenomicsDNA methylationProteinsProteomicsMonoclonal antibodiesAptamersBasics of molecular diagnosticsTracking DNA: the Southern blotPulsed-field gel electrophoresisDNA ProbesThe polymerase chain reactionBasic Principles of PCRTarget selectionDetection of amplified DNAImpact of human genome project on molecular diagnosticsMapping and sequencing of structural variation from human genomes1000 Genomes ProjectHuman Variome ProjectRole of bioinformatics in molecular diagnosticsSystems biology approach to molecular diagnosticsSynthetic biology and molecular diagnosticsBiomarkersApplications of molecular diagnostics 2. Molecular Diagnostic Technologies 3. Biochips, Biosensors, and Nanobiotechnology 4. Proteomic Technologies for Molecular Diagnostics 5. Molecular Diagnosis of Genetic Disorders 6. Molecular diagnosis of cardiovascular disorders 7. Molecular Diagnosis of Infections 8. Molecular Diagnosis of Cancer 9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare 10. Molecular Diagnostics in Forensic Medicine and Biological Warfare 11. References Part Two 12. Ethics, Patents and Regulatory issues 13. Markets for Molecular Diagnostics 14. Companies involved in molecular diagnostics For more information about this report visit https://www.researchandmarkets.com/r/qqfm4c CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
A US man has reportedly been arrested and charged after telling a match "I did storm the Capitol".
In the next few days, the White House will unveil long-awaited details for most of the tax-the-rich proposals President Biden has been promising since last year's campaign — laying the groundwork ahead of an April 28 speech to lawmakers timed around his first 100 days in office.What we're hearing: Think of Biden's plans to increase the top marginal rate to 39.6% and the capital gains rate to 43.4% for the wealthiest Americans as opening bids.Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for freeDemocrats close to the White House believe that the amount of revenue that the IRS can collect on capital gains actually decreases past a certain point, probably in the low 30% range. That means the ultimate capital gains rate could be well below 43.4%Officials haven't yet made clear whether the capital gains rate would apply in 2022 — or in 2021, which would allow the IRS to harness some of the massive earning in the equities market this year. Why it matters: Practically and politically, the White House needs to buy-in from Congress to find fresh revenue to pay for the next phase of his plan to reshape the American economy.That includes more than $1 trillion in new spending on child care, free community college and paid family leave that he'll lay out in his first address to a joint session of Congress.Driving the news: We saw some jitters Thursday around leaked elements of the plans as administration officials worked to finalize their rollout — even though Biden has been telegraphing his plans for months and experts don't expect major surprises and also don't expect many of the proposed rates to be fully adopted.The Dow closed down more than 300 points after Bloomberg News first reported on some of the plan's expected details.Goldman Sachs sent out a research note Thursday evening entitled, “No Surprises in President Biden’s Reported Capital Gains Proposal." It predicted: “We expect Congress will pass a scaled back version of this tax increase." The big picture: The tax component to Biden’s American Families Plan is animated by two principles.Philosophically, he wants the rich to contribute a larger share of federal taxesPractically, he needs to find fresh revenue to pay for the next phase of his plan to reshape the American economy. Biden has long telegraphed his intent on personal income taxes, just like he did on trying to raise the corporate rate from 21% to 28%.Throughout the campaign, Biden vowed to raise taxes on households that make more $400,000 and to treat capital gains as regular income.By the numbers: Biden arrives at his headline 43.4% rate on capital gains for assets over $1 million by taxing them at the top marginal rate, which he wants to increase to 39.6%, plus the additional 3.8% existing surtax from the Affordable Care Act.Biden is making an end-run around "carried interest," a term of art in the private equity industry, which allows employees to have some of their compensation taxed at 20%, instead of the top marginal rate, currently at 37%. Biden would end carried interest without calling attention to it. What we're watching: Biden also is likely to raise more revenue from the wealthy by making changes to estate taxes.Biden wants to impose so-called "stepped up basis" for accounting purposes, and value assets when they are passed on to an heir, not at their original cost.The White House thinks that change could lead more individual to liquidate their assets before they die, allowing the IRS to tax them then instead of encouraging families to keep passing on them for more favorable tax treatment. More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free
Major players in the oral biologics and biosimilar market are Novartis, Rani Therapeutics, Eli Lilly and Co. , AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd.New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Oral Biologics & Biosimilar Drugs Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06065185/?utm_source=GNW and Allergan plc.The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to $4.1 billion in 2021 at a compound annual growth rate (CAGR) of 16.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $8.69 billion in 2025 at a CAGR of 21%.The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer.Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics.Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer’s, multiple sclerosis, HIV/AIDS and other serious conditions.North America was the largest region in the global oral biologics & biosimilar drugs market, accounting for 46% of the market in 2019.Asia Pacific was the second largest region accounting for 24% of the global regional preview market.Eastern Europe was the smallest region in the global oral biologics & biosimilar drugs market.The oral biologics and biosimilar market covered inthis report is segmented by therapy into lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors. It is also segmetned by disease into asthma, crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis and others, by molecule type into vaccines, proteins & peptides, monoclonal antibodies, others and by distribution channel into hospital pharmacies, retail pharmacies, online pharmaciesStringent regulations imposed on approval of biosimilar is anticipated to hinder the growth of oral biologics and biosimilar market in the forecast period.The governments of different regions impose different rules regarding the production and use of biologics and biosimilars.Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars.The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics.In February 2019, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar market.The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars.The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin.This is also promoting competition among various biosimilar manufacturers.Following the trend, Mylan, a USA based pharmaceuticals company, in partnership with Biocon launched biosimilar insulin glargine named Semglee, in 2019 in Australia.Biocon is an Indian based biopharmaceutical company.In 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes.Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market.Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases.Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body.According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths.The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market.Read the full report: https://www.reportlinker.com/p06065185/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Cathie Wood and Warren Buffett are perhaps the two best-known investors of our time. Buffett has long been considered the greatest investor of all time, having grown his Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) holding company to be one of the most valuable companies in the world, making early investors rich along with him. Wood, on the other hand, has made a name for herself quite recently, as her ARK Invest exchange-traded funds (ETFs), including the flagship ARK Innovation ETF (NYSEMKT: ARKK), crushed the market last year, with ARK Innovation jumping 149%.
Germany called for greater efforts by Serbia and Kosovo in talks about a normalisation of their relationship, more than 20 years after Belgrade lost control of its former southern province. Kosovo eventually declared independence from neighbouring Serbia in 2008, but Belgrade, backed by Russia, China, and some European Union member states, refuses to recognise it. "It is the right time to continue the normalisation process, and to achieve results," German Foreign Minister Heiko Maas told a live-streamed news briefing after a meeting with Serbian President Aleksandar Vucic in Belgrade on Friday.
The government borrowed £303bn in the year to March, reflecting the cost of measures to support the economy.
The "Plastics Beyond Petroleum BioMass+GHG+Recycling; Disrupting Petroleum as Feedstock" conference has been added to ResearchAndMarkets.com's offering.
Yahoo Home